Stratos Wealth Partners LTD. Acquires 86,730 Shares of Recursion Pharmaceuticals, Inc. $RXRX

Stratos Wealth Partners LTD. grew its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 724.3% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 98,704 shares of the company’s stock after acquiring an additional 86,730 shares during the period. Stratos Wealth Partners LTD.’s holdings in Recursion Pharmaceuticals were worth $499,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. AlphaQuest LLC bought a new stake in Recursion Pharmaceuticals in the first quarter worth approximately $36,000. GAMMA Investing LLC grew its position in Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after acquiring an additional 2,026 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in Recursion Pharmaceuticals in the second quarter worth approximately $51,000. ADG Wealth Management Group LLC bought a new stake in Recursion Pharmaceuticals in the first quarter worth approximately $55,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Recursion Pharmaceuticals in the first quarter worth approximately $57,000. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Price Performance

Shares of Recursion Pharmaceuticals stock opened at $5.73 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $12.36. The firm has a fifty day moving average price of $5.17 and a two-hundred day moving average price of $5.17. The company has a market cap of $2.49 billion, a PE ratio of -3.22 and a beta of 0.91.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The company had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. During the same period last year, the company earned ($0.40) earnings per share. Recursion Pharmaceuticals’s revenue for the quarter was up 33.3% on a year-over-year basis. Analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, insider Najat Khan sold 36,599 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $5.52, for a total value of $202,026.48. Following the completion of the sale, the insider directly owned 668,197 shares of the company’s stock, valued at $3,688,447.44. This represents a 5.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.43% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

RXRX has been the subject of several recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Wednesday, October 8th. Finally, Morgan Stanley initiated coverage on shares of Recursion Pharmaceuticals in a report on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 price objective for the company. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $7.25.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.